Exchange: NASDAQ
Industry: Biotechnology
Last Trade: 4:00 PM ET 2/9/2012
Last 10 Quotes:
What's This?
| Most Recent Quarter ($) | Same Quarter Last Year ($) | % Change | |
| EPS, Pro Forma | 1.50 | 1.41 | 6.38 |
| EPS, GAAP | 1.23 | 0.99 | 24.24 |
| Consensus Estimate | 1.46 | 1.23 | 18.70 |
| Trailing 12 Months | Year-Earlier Period | % Change | |
| EPS, Pro Forma | 5.84 | 5.84 | 0.00 |
| EPS, GAAP | 5.04 | 3.96 | 27.27 |
| Consensus Estimate | 5.75 | NA | NA |
| BIIB | Industry Average | |
| P/E (TTM) | 23.73 | 86.30 |
| P/E (Forward) | 19.54 | -4.30 |
| PEG Ratio | 1.50 | -0.21 |
| Price/Sales | 5.80 | 4.64 |
| Beta | 0.86 | 1.01 |
| 6:07 PM | 2/3/2012 | Biogen: Government Investigating Company's Promotional Practices |
| 1:04 PM | 1/31/2012 | 2nd UPDATE: Biogen 4Q Net Up 25%; Investing In Pipeline |
| 2/9/2012 | A Case for Switching to Biogen From Amgen (Barrons.com) |
| 2/6/2012 | Teva Downgraded: Upside Looks Limited (Barrons.com) |
| 2/3/2012 | Finding companies that have all the right stuff can produce winners. (The Motley Fool) |
| 1/31/2012 | Biogen's Net Rises 25% (WSJ.com) |
| 1/31/2012 | This Blockbuster Drug Just Got Better (The Motley Fool) |
| 1/31/2012 | Stocks to Watch: Eli Lilly, Biogen Idec and More (WSJ.com) |
| 1/30/2012 | That might depend on which kind of investor you are. (The Motley Fool) |
| 1/30/2012 | The biotech withdraws its application to delay a test. (The Motley Fool) |
![[sm0212smart]](http://s.wsj.net/public/resources/images/PF-AB863_sm0212_C_20120118122431.jpg)
![[smfineprint]](http://s.wsj.net/public/resources/images/PF-AB821_smfine_C_20120111122044.jpg)
![[sm0212funds]](http://s.wsj.net/public/resources/images/PF-AB839_sm0212_C_20120113140400.jpg)
![[sm0212ten]](http://s.wsj.net/public/resources/images/PF-AB840_sm0212_C_20120117120334.jpg)
